Rituximab in immunologic glomerular diseases

mAbs

Volumn 4, Issue 2, 2012, Pages 198-207

  Ejaz, A Ahsan ^a   Asmar, Abdo ^b   Alsabbagh, Mourad M ^a   Ahsan, Nasimul ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Glomerular diseases; Rejection; Rituximab; Transplant

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; IMMUNOGLOBULIN; LEVAMISOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BULLOUS SKIN DISEASE; C1Q GLOMERULOPATHY; CRYOGLOBULINEMIA; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESISTANCE; GLOMERULOPATHY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTACTOID GLOMERULOPATHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE SCLEROSIS; NEPHROTIC SYNDROME; NONAMYLOID FIBRILLARY GLOMERULOPATHY; NONHODGKIN LYMPHOMA; PROPHYLAXIS; PURE RED CELL ANEMIA; RECURRENT DISEASE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VASCULITIS; ALLOGRAFT; B LYMPHOCYTE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY DISEASES; LYMPHOCYTE DEPLETION; PATHOLOGY; PROCEDURES;

ALLOGRAFTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION;

EID: 84858228135     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.2.19286     Document Type: Review

References (114)

1. Chinen J, Shearer WT. Advances in basic and clinical immunology in 2010. J Allergy Clin Immunol 2011; 127:336-41; PMID:21281863; http://dx.doi.org/10. 1016/j.jaci.2010.11.042.
2. Lee SL, Ballow M. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. J Allergy Clin Immunol 2010; 125:814-20; PMID:20371395; http://dx.doi.org/10.1016/j.jaci.2010.02.025.
3. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4:734-44; PMID:19279120; http://dx.doi.org/10.2215/CJN. 05231008.
4. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1:738-48; PMID:17699281; http://dx.doi.org/10.2215/CJN. 01080905.
5. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-81; PMID:15201414; http://dx.doi.org/10.1056/NEJMoa032534.
6. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse and re-treatment. Arthritis Rheum 2006; 54:2970-82; PMID:16947528; http://dx.doi.org/10.1002/art.22046.
7. El-Zoghby ZM, Grande JP, Fraile MG, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 2009; 9:2800-7; PMID:19845581; http://dx.doi.org/10.1111/j.1600-6143.2009.02851. x.
8. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010; 5:2363-72; PMID:21030574; http://dx.doi.org/10.2215/CJN.06720810.
9. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15:8-10; http://dx.doi.org/10.1097/MOT.0b013e3283342712; PMID:19890210.
10. Crew RJ, Ratner LE. ABO-incompatible kidney transplantation: current practice and the decade ahead. Curr Opin Organ Transplant 2010; 15:526-30; http://dx.doi.org/10.1097/MOT.0b013e32833bfbba; PMID:20613520.
11. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22:7359-68; PMID:14576843; http://dx.doi.org/10. 1038/sj.onc.1206939.
12. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121:1121-32; PMID:7684739; http://dx.doi.org/10.1083/jcb.121.5.1121.
13. Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase Cgamma1 and PLC phospholipase Cgamma2. J Immunol 1993; 151:4494-504; PMID:7691952.
14. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Blood 2002; 99:1314-9; PMID:11830481; http://dx.doi.org/10.1182/blood.V99.4.1314.
15. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3:85; PMID:21632984; http://dx.doi.org/10.1126/scitranslmed.3002231.
16. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99:1038-43; PMID:11807010; http://dx.doi.org/10.1182/ blood.V99.3.1038.
17. Treon SP, Mitisiades C, Mitisiades N, Young G, Doss D, Schlossman SF, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24:263-71; http://dx.doi.org/10.1097/00002371-200105000-00011.
18. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
19. Shimada M, Ishimoto T, Lee PY, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, et al. Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF{kappa}B-dependent pathway. Nephrol Dial Transplant 2012; 27:81-9; PMID:21617192; http://dx.doi.org/10.1093/ndt/gfr271.
20. Dall'Aglio P, Meroni PL, Barcellini W, Brigati C, Chizzolini C, De Bartolo G, et al. Altered expression of B lymphocyte surface immunoglobulins in minimal change nephrotic syndrome and focal glomerulosclerosis. Nephron 1984; 37:224-8; PMID:6611510; http://dx.doi.org/10.1159/000183253.
21. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23:1269-79; PMID:18465150; http://dx.doi.org/10.1007/ s00467-008-0814-1.
22. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009; 24:1321-8; PMID:19421786; http://dx.doi.org/10. 1007/s00467-009-1191-0.
23. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010; 5:2207-12; PMID:20798255; http://dx.doi.org/10.2215/CJN.03470410.
24. Sellier-Leclerc AL, Macher MA, Loirat C, Guérin V, Watier H, Peuchmaur M, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25:1109-15; PMID:20238230; http://dx.doi.org/10.1007/s00467-010-1465-6.
25. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:1308-15; PMID:21566104; http://dx.doi.org/10.2215/CJN. 09421010.
26. Sinha A, Bagga A, Gulati A, Hari P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. [Epub ahead of print]. Pediatr Nephrol 2012; 27:235-41; PMID:21922213; http://dx.doi.org/10. 1007/s00467-011-1997-4.
27. Haffner D, Fischer DC. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009; 24:1433-8; PMID:19495800; http://dx.doi.org/10.1007/s00467-009-1226-6.
28. Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int 2009; 76:487-91; PMID:19494796; http://dx.doi.org/10.1038/ki.2009.204.
29. van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011; 26:881-92; PMID:21229269; http://dx.doi.org/10.1007/s00467-010-1717-5.
30. Benz K, Dötsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004; 19:794-7; PMID:15071769; http://dx.doi.org/10.1007/s00467-004-1434-z.
31. Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006; 21:1698-700; PMID:16932900; http://dx.doi.org/10.1007/s00467-006-0228-x.
32. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007; 356:2751-2; PMID:17596616; http://dx.doi.org/10.1056/NEJMc063706.
33. Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008; 23:481-5; PMID:17973121; http://dx.doi.org/10.1007/s00467-007-0640-x.
34. Suri M, Tran K, Sharma AP, Filler G, Grimmer J. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 2008; 40:807-10; PMID:18491215; http://dx.doi.org/10.1007/s11255-008-9393-0.
35. Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N, et al.; Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4:1317-23; PMID:19578004; http://dx.doi.org/10.2215/CJN. 00570109.
36. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11-21; PMID:19571279; http://dx.doi.org/10. 1056/NEJMoa0810457.
37. 2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011; 26:2526-32; PMID:21633097; http://dx.doi.org/10. 1093/ndt/gfr247.
38. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543-50; PMID:21784898; http://dx.doi.org/10.1681/ASN.2010111125.
39. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008; 3:1652-9; PMID:18684896; http://dx.doi.org/10.2215/CJN.01730408.
40. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73:117-25; PMID:17943078; http://dx.doi.org/10.1038/sj.ki.5002628.
41. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14:1851-7; PMID:12819245; http://dx.doi.org/10. 1097/01.ASN.0000071511.35221.B3.
42. Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4:1083-8; PMID:19478097; http://dx.doi.org/10.2215/CJN.06041108.
43. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, et al.; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21:697-704; PMID:20110379; http://dx.doi.org/10.1681/ASN.2009080861.
44. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222-33; PMID:20039413; http://dx.doi.org/10.1002/art.27233.
45. Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 2008; 47:821-7; PMID:18397955; http://dx.doi.org/10.1093/rheumatology/ken071.
46. Camous L, Melander C, Vallet M, Squalli T, Knebelmann B, Noël LH, et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 2008; 52:346-52; PMID:18572292; http://dx.doi.org/10.1053/j.ajkd.2008.03.036.
47. Moroni G, Gallelli B, Banfi G, Leoni A, Messa P. Rituximab monotherapy for remission induction of proliferative lupus nephritis flares: description of 3 cases. J Nephrol 2010; 23:357-61; PMID:20383866.
48. Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24:3717-23; PMID:19617257; http://dx.doi.org/10.1093/ndt/gfp336.
49. Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 2009; 48:892-8; PMID:19478041; http://dx.doi.org/10.1093/rheumatology/ kep124.
50. Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011; 20:709-16; PMID:21478286; http://dx.doi.org/ 10.1177/0961203310395802.
51. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12:783-7; PMID:14596429; http://dx.doi.org/10.1191/0961203303lu453cr.
52. Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes and predictors of response. Ann Rheum Dis 2008; 67:330-4; PMID:17827182; http://dx.doi.org/10. 1136/ard.2007.079095.
53. Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009; 24:2157-60; PMID:19179411; http://dx.doi.org/10.1093/ndt/gfp002.
54. Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17:191-7; PMID:17564773; http://dx.doi.org/ 10.1007/s10165-007-0565-z.
55. Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56:1263-72; PMID:17393458; http://dx.doi.org/10.1002/art.22505.
56. Roccatello D, Baldovino S, Alpa M, Rossi D, Napoli F, Naretto C, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008; 26:67-71; PMID:18799057.
57. Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4:579-87; PMID:19261822; http://dx.doi.org/10.2215/CJN.04030808.
58. Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiguchi O, et al. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 2009; 89:305-9; PMID:19308659; http://dx.doi.org/10.1007/ s12185-009-0269-6.
59. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67:1724-31; PMID:18250115; http://dx.doi.org/10.1136/ard.2007.083162.
60. Holden NJ, Williams JM, Morgan MD, Challa A, Gordon J, Pepper RJ, et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis 2011; 70:2229-33; PMID:21859691; http://dx.doi.org/10.1136/ard.2011.153890.
61. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156-68; PMID:19565480; http://dx.doi.org/10.1002/art.24637.
62. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45:1432-6; PMID:16632482; http://dx.doi.org/10.1093/rheumatology/kel098.
63. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262-8; PMID:15641078; http://dx.doi.org/10.1002/art.20718.
64. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-7; PMID:16224107; http://dx.doi.org/10.1164/rccm.200507-1144OC.
65. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-20; PMID:20647198; http://dx.doi.org/10.1056/NEJMoa0909169.
66. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-32; PMID:20647199; http://dx.doi.org/10. 1056/NEJMoa0909905.
67. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody- associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394-400; PMID:20498238; http://dx.doi.org/10.2215/CJN.08821209.
68. Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. [Epub ahead of print]. Ann Rheum Dis 2011; PMID:22021864.
69. Mansfield N, Hamour S, Habib AM, Tarzi R, Levy J, Griffith M, et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 2011; 26:3280-6; PMID:21414973; http://dx.doi.org/10.1093/ndt/gfr127.
70. Wink F, Houtman PM, Jansen TL. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Clin Rheumatol 2011; 30:293-300; PMID:21053035; http://dx.doi.org/10.1007/s10067-010- 1612-2.
71. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus Peg-interferonalpha/ribavirin compared with Peg-interferon-alpha/ ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116:326-34; PMID:20439619; http://dx.doi.org/10.1182/blood-2009-10-248518.
72. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004; 43:34-8; PMID:15112197; http://dx.doi.org/10.1053/j.ajkd.2003.12.057.
73. Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11:48-55; PMID:21821153; http://dx.doi.org/10.1016/j.autrev.2011.07.005.
74. Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006; 38:2308-10; PMID:16980074; http://dx.doi.org/10. 1016/j.transproceed.2006.06.131.
75. Kawano N, Ikeda N, Yoshida S, Sugio Y, Yamashita K, Uezono S, et al. Successful treatment of cryoglobulinemic glomerulonephritis derived from Waldenström's macroglobulinemia by rituximab-CHOP and tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Int J Hematol 2010; 92:391-7; PMID:20686877; http://dx.doi.org/10.1007/s12185-010- 0638-1.
76. Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 2011; 6:1609-16; PMID:21700823; http://dx.doi.org/10.2215/CJN. 10611110.
77. Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012; 44:49-54; PMID:21885355; http://dx.doi.org/10.1016/j.dld. 2011.07.016.
78. Stamataki Z, Tilakaratne S, Adams DH, McKeating JA. Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS One 2011; 6:25789; PMID:21991396; http://dx.doi.org/10.1371/journal.pone.0025789.
79. Sinha A, Nast CC, Hristea I, Vo AA, Jordan SC. Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clin Exp Nephrol 2011; 15:164-70; PMID:21107633; http://dx.doi.org/10.1007/s10157-010- 0377-x.
80. Collins M, Navaneethan SD, Chung M, Sloand J, Goldman B, Appel G, et al. Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis 2008; 52:1158-62; PMID:18823685; http://dx.doi.org/10.1053/j.ajkd.2008.07.011.
81. Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H, et al. Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. Eur J Haematol 2006; 77:527-9; PMID:17042766; http://dx.doi.org/10. 1111/j.1600-0609.2006.00758.x.
82. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002; 71:105-8; PMID:12353309; http://dx.doi.org/10.1002/ajh.10204.
83. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002; 28:385-91; PMID:12367582; http://dx.doi.org/10.1006/bcmd.2002.0522.
84. Lombardi AM, de Marinis GB, Scandellari R, Magalini F, Sansoni P, Ballerini PF, et al. Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. Thromb Res 2010; 126:154-6; PMID:20193960; http://dx.doi.org/10.1016/j.thromres.2010.02.005.
85. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118:1746-53; PMID:21636861; http://dx.doi.org/10.1182/blood-2011-03-341131.
86. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, et al.; French Thrombotic Microangiopathies Reference Center; Experience of the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Crit Care Med 2012; 40:104-11; PMID:21926591; http://dx.doi.org/10.1097/CCM.0b013e31822e9d66.
87. Klipa D, Mahmud N, Ahsan N. Antibody immunosuppressive therapy in solid organ transplant: Part II. MAbs 2010; 2:607-12; PMID:20948291; http://dx.doi.org/10.4161/mabs.2.6.13586.
88. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4:996-1001; PMID:15147435; http://dx.doi.org/10.1111/j.1600-6143.2004.00454.x.
89. Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85:1745-54; PMID:18580466; http://dx.doi.org/10.1097/TP.0b013e3181726849.
90. Tydén G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87:1325-9; PMID:19424032; http://dx.doi.org/10.1097/TP.0b013e3181a235fd.
91. Clatworthy MR, Watson CJ, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360:2683-5; PMID:19535812; http://dx.doi.org/10.1056/NEJMc0808481.
92. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753-60; PMID:18294345; http://dx.doi.org/10.1111/j.1600- 6143.2008.02159.x.
93. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immunoglobulin for desensitization during renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87:1246-55; PMID:19384174.
94. Kaposztas Z, Podder H, Mauiyyedi S, Illoh O, Kerman R, Reyes M, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23:63-73; PMID:19200217; http://dx.doi.org/10.1111/j.1399-0012. 2008.00902.x.
95. Mulley WR, Hudson FJ, Tait BD, Skene AM, Dowling JP, Kerr PG, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009; 87:286-9; PMID:19155986; http://dx.doi.org/10.1097/TP.0b013e31819389cc.
96. Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat Clin Pract Nephrol 2008; 4:446-57; PMID:18560395; http://dx.doi.org/10.1038/ncpneph0854.
97. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103-9; PMID:12110738; http://dx.doi.org/10.1056/NEJMoa013036.
98. Wadei HM, Geiger XJ, Mai ML. Recurrent glomerular diseases in the allograft: risk factors and management. In Ahsan N, Eds. Chronic allograft failure: natural history, pathogenesis, diagnosis and management. Austin TX, Landes Bioscience 2008; 200-21.
99. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68:635-41; PMID:10507481; http://dx.doi.org/10.1097/00007890-199909150-00007.
100. Damodar A, Mustafa R, Bhatnagar J, Panesar M, Gundroo A, Zachariah M, et al. Use of anti-CD20 antibody in the treatment of post-transplant glomerulonephritis. Clin Transplant 2011; 25:375-9; PMID:20384712; http://dx.doi.org/10.1111/j.1399-0012.2010.01245.x.
101. Dall'Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999; 34:1048-55; PMID:10585314; http://dx.doi.org/10.1016/S0272-6386(99)70010-7.
102. Rodríguez-Ferrero M, Ampuero J, Anaya F. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 2009; 41:2406-8; PMID:19715934; http://dx.doi.org/10.1016/j.transproceed.2009.06.044.
103. Westphal S, Hansson S, Mjörnstedt L, Mölne J, Swerkersson S, Friman S. Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin and rituximab. Transplant Proc 2006; 38:2659-60; PMID:17098031; http://dx.doi.org/10.1016/j.transproceed.2006.07.034.
104. Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232-9; PMID:19384172; http://dx.doi.org/10.1097/TP.0b013e31819f12be.
105. Dello Strologo L, Guzzo I, Laurenzi C, Vivarelli M, Parodi A, Barbano G, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009; 88:417-20; PMID:19667947; http://dx.doi.org/10.1097/TP.0b013e3181aed9d7.
106. Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007; 20:102-5; PMID:17181660; http://dx.doi.org/10.1111/j.1432-2277.2006.00395.x.
107. Sakai K, Takasu J, Nihei H, Yonekura T, Aoki Y, Kawamura T, et al. Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin Transplant 2010; 24:60-5; PMID:20590697; http://dx.doi.org/10.1111/j.1399-0012.2010.01279.x.
108. Kaito H, Kamei K, Kikuchi E, Ogura M, Matsuoka K, Nagata M, et al. Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and ciclosporin. Pediatr Nephrol 2010; 25:957-9; PMID:20033219; http://dx.doi.org/10.1007/s00467-009-1410-8.
109. Sprangers B, Lefkowitz GI, Cohen SD, Stokes MB, Valeri A, Appel GB, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010; 5:790-7; PMID:20185599; http://dx.doi.org/10.2215/CJN.04120609.
110. Sathyan S, Khan FN, Ranga KV. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. Transplant Proc 2009; 41:3953-5; PMID:19917422; http://dx.doi.org/10.1016/j.transproceed.2009.03.100.
111. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10:89-98; PMID:19656128; http://dx.doi.org/10.1111/j.1600-6143.2009.02785.x.
112. Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology (Carlton) 2009; 14:696-9; PMID:19796030; http://dx.doi.org/10.1111/j.1440-797. 2009.01168.x.
113. Bitzan M, Ouahed JD, Carpineta L, Bernard C, Bell LE. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol 2010; 25:1163-7; PMID:20140460; http://dx.doi.org/10.1007/s00467-010-1447-8.
114. Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009; 9:244-5; PMID:19133934; http://dx.doi.org/10.1111/j.1600-6143.2008.02499.x.